BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25455280)

  • 1. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the potential for thrombopoietic agents in acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thrombopoietin receptor agonists for platelet disorders.
    Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
    Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New thrombopoietic growth factors.
    Kuter DJ
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S347-56. PubMed ID: 19778863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin-receptor agonists.
    Basciano PA; Bussel JB
    Curr Opin Hematol; 2012 Sep; 19(5):392-8. PubMed ID: 22872157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
    Vibor M; Rogulj IM; Ostojic SK
    Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
    Siegal D; Crowther M; Cuker A
    Semin Hematol; 2013 Jan; 50 Suppl 1(0 1):S18-21. PubMed ID: 23664510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
    Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
    J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.